Showing results (611-620 of 963) with videos related to
Sort By:
Pageof 97
Genes, Brain, and Behavior|April 3, 2012
Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTASF Tassone, C M Greco, M R Hunsaker, et al.Journal of Neurodevelopmental Disorders|June 30, 2010
Aging in fragile X syndromeAgustini Utari, Evan Adams, Elizabeth Berry-Kravis, et al.Hepatology (Baltimore, Md.)|October 26, 2019
Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral InfectionMarianne Martinello, Chloe Orkin, Graham Cooke, et al.Hepatology International|February 18, 2016
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosisEdward J Gane, Régine Rouzier, Tarek Hassanein, et al.Journal of Viral Hepatitis|March 16, 2013
Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis BY Wang, S Thongsawat, E J Gane, et al.Hepatology (Baltimore, Md.)|April 5, 2013
Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levelsMilan J Sonneveld, Bettina E Hansen, Teerha Piratvisuth, et al.Journal of Medicinal Chemistry|May 30, 1998
Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitorsS F Martin, G O Dorsey, T Gane, et al.Journal of Viral Hepatitis|April 17, 2018
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infectionM Martinello, S Bhagani, E Gane, et al.Pharmacoeconomics|March 12, 2003
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis CJens Rasenack, Stefan Zeuzem, S Victor Feinman, et al.Journal of Viral Hepatitis|December 10, 2016
Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirinS Alqahtani, R Ozaras, V Isakov, et al.Pageof 97